Skip to content

LeMaitre target upped by Stifel after beat

April 27, 2017

Stifel raised its price target on LeMaitre Vascular (NASDAQ: LMAT) to $29.00 (from $25.00) while maintaining a Buy rating. EPS of $0.16 grew 40%+ Y/Y. A lower than projected 1Q tax rate added $0.01-0.02 of EPS. But even excluding this benefit, the results still would have exceeded EPS expectations by $0.01-0.02.

For 2017, the company now expects sales at $100.5M, up from $99M previously. Importantly, the $1.5M guidance raise was roughly $900K above and beyond the1Q sales upside surprise.


From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: